



**Supplemental Figure 1. Examples of cytokine staining and gates showing staining controls.** Spleen cells were stimulated with PMA plus ionomycin and stained intracellularly for the indicated cytokines, 7 days after SRBC immunization as in Figure 6. Plots are gated on CD4<sup>+</sup> cells. Gated regions show cytokine-positive cells. Isotype controls for each Ab were used to set gates; for isotype controls, 0-1% of the cells were in the gated region for all cytokines analyzed.



**Supplementary Figure 2. Tfh cell intrinsic regulation of transcription factors and cytokines by Stat3.** (A) T<sub>FH</sub> cells in the Peyer's patches (PPs) of WT and STAT3KO mice were sorted by FACS and RNA isolated post-sort. Tbx21 (Tbet) mRNA levels were assayed by QPCR. (B-D) WT and STAT3KO OTII TCR transgenic CD45.2+ CD4+ T cells were transferred to CD45.1+ BoyJ mice, and the recipient BoyJ mice were immunized with OVA-Alum. T<sub>FH</sub> cells were analyzed at 7 days after immunization. Graphs show Tbet, Bcl6 and Gata3 MFIs of CD45.1-TFH cells, where each symbol represents one mouse (n=3, mean ± SEM). (E-G) Cytokines in T<sub>FH</sub> cell populations in the PPs of bone marrow chimeras were measured by intracellular cytokine staining (ICS) following PMA plus ionomycin staining in vitro.



**Supplemental Figure 3. Increased proliferation and decreased death of Stat3-deficient CD4 T cells.** A-B) WT and STAT3KO OTII TCR transgenic CD45.2+ CD4+ T cells were transferred to CD45.1+ BoyJ mice and immunized with OVA-Alum as in Figure 6. A) Histogram plot of Cell Tracker Violet (CTV)-labeled WT and STAT3KO OTII CD4+ T cells at 6 dpi with OVA-Alum. B) Graphs of average MFI of CTV-labeled WT and STAT3KO OTII CD4+ T cells. Each symbol represents one mouse (n=3, mean ± SEM). \*\**P* < 0.01 (*t*-test). C) Annexin V+ percentage of T<sub>FH</sub> cells assayed *ex vivo* from spleen 7 dpi with SRBC in WT and STAT3KO mice. Each symbol represents one mouse (n=4-5, mean ± SEM). \**P* < 0.05 (*t*-test). D) Annexin V+ percentage of T<sub>FH</sub> cells assayed *ex vivo* from PP (n=4-5, mean ± SEM). \*\**P* < 0.01 (*t*-test). E) 7 dpi with SRBC, average percentage of activated Caspase3+ (aCaspase3+) cells in FACS-isolated spleen T<sub>FH</sub> cells and non-T<sub>FH</sub> cell populations, stimulated with anti-CD3 Ab overnight *in vitro*. (n=3, mean ± SEM). \*\*\**P* < 0.001 (ANOVA).

**Supplemental Figure 4. Defective Suppression of IL-4 by Bcl6 in Stat3-deficient T cells.** WT and STAT3KO OTII TCR transgenic CD4<sup>+</sup> T cells were cultured under Tfh conditions with APC and OVA peptide *in vitro* for 3 days. (A) Cells were stimulated with PMA plus ionomycin and analyzed for IFN $\gamma$  and IL-4 ICS and flow cytometry after just 3 days of culture. (B) Part of the primary culture was put into secondary culture under Th2 conditions with APC and OVA peptide *in vitro* for 5 days, before being stimulated with PMA plus ionomycin and analyzed for IFN $\gamma$  and IL-4 ICS and flow cytometry. Graphs show average percentages of IFN $\gamma$ +IL-4<sup>-</sup>, IFN $\gamma$ +IL-4<sup>+</sup> and IFN $\gamma$ -IL-4<sup>+</sup> cell CD4<sup>+</sup> T cells (n=3, mean  $\pm$  SEM). \*\*\**P* < 0.001 (ANOVA).

